FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.